Research involving non-human primate (NHP) models can provide information that is difficult to obtain from conventional preclinical systems alone. Clinically relevant anatomy, disease procedures, imaging, pharmacology and longitudinal assessment may help researchers evaluate how a therapeutic approach behaves before clinical development.
This page presents selected scientific publications and conference contributions involving Prisys Biotechnologies. The records include publications with Prisys-affiliated authors, collaborative NHP model-development studies, and partner research programs supported by Prisys animal research capabilities.
For each record, we identify the publication type, therapeutic area, NHP model and the documented role of Prisys. This distinction is important: a publication may involve Prisys authorship, scientific collaboration or contract research support, and these roles are not interchangeable.
Selected publications
The records below are grouped by the nature of the Prisys contribution. The first group contains collaborative NHP model-development or model-supported studies. The second group contains additional selected publications with Prisys-affiliated authors or documented Prisys research support.
Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia
Nature Communications·2020·Peer-reviewed research article·Hematology and hemophilia
Study overview
This study evaluated two inhibitory monoclonal antibodies against activated protein C (APC) as potential treatments for hemophilia. The researchers compared an active-site antibody with a non-active-site antibody designed to inhibit APC's anticoagulant activity while preserving its cytoprotective function.
The study included normal monkey and hemophilic monkey experiments. The non-active-site antibody showed dose-dependent efficacy in hemophilic monkeys and was better tolerated than the active-site antibody in normal monkeys. The work illustrates how NHP models can be used to assess both therapeutic activity and safety when the target biology is closely linked to hemostasis.
Prisys involvement
The publication is listed as a collaborative NHP research record associated with Prisys Biotechnologies. Prisys is not presented as the sole author of the study; the original publication remains the source for authorship, methods and results.
Related Prisys capabilities
- ▪Hemophilia and coagulation-related NHP research
- ▪Evaluation of biologic therapies in NHPs
- ▪Hemostasis and safety endpoints
- ▪Dose-response and tolerability assessment
- ▪Translational pharmacology for human-specific targets
Using skin biopsies to measure target occupancy of anti-fibrotic molecules: assay development and application for zampilimab in a primate model of chronic kidney disease and in healthy human volunteers
BMC Nephrology·2025·Peer-reviewed research article·Renal disease, fibrosis and target engagement
Study overview
This study developed a skin biopsy-on-biopsy approach to assess target occupancy of zampilimab, an anti-fibrotic therapeutic targeting transglutaminase 2 (TG2). The approach was evaluated alongside a cynomolgus monkey model of chronic kidney disease and compared with target engagement measurements in the kidney.
The study reported a relationship between target occupancy measured in skin and target engagement in the kidney. It also evaluated a dermal wound model in healthy human volunteers as a more accessible tissue-based approach for translational pharmacology.
Prisys involvement
The publication is listed as a collaborative NHP model-development and translational assay study involving Prisys Biotechnologies. The specific contribution of Prisys is presented separately from the authorship and findings reported in the original article.
Related Prisys capabilities
- ▪Cynomolgus monkey chronic kidney disease models
- ▪Unilateral ureteral obstruction and renal fibrosis research
- ▪Target engagement and target occupancy studies
- ▪Tissue sampling and immunofluorescence-based assays
- ▪Translational biomarker and pharmacology support
Modified hTERT treatment ameliorates pressure overload-induced heart failure
eBioMedicine·2026·Peer-reviewed research article·Cardiovascular disease and gene therapy
Study overview
This study evaluated a modified human telomerase reverse transcriptase strategy delivered by AAV9 for the treatment of pressure overload-induced heart failure. The researchers examined telomere shortening in cynomolgus monkey and human heart failure samples and assessed the therapeutic mechanism in mouse and human induced pluripotent stem cell-derived cardiomyocyte models.
The study reported that the modified hTERT construct improved cardiac function and reduced fibrosis in pressure overload-induced mouse heart failure. Mechanistic analyses examined telomere-associated DNA damage, p53 signaling, mitochondrial function, oxidative stress and inflammation.
Prisys involvement
Cynomolgus monkey heart samples used in the study were obtained from Shanghai Prisys Biotechnologies Co., Ltd. The publication is listed as a collaborative NHP research record because Prisys contributed to the availability of NHP heart failure material used for translational analysis. The record does not attribute development or testing of the JV101 gene therapy to Prisys.
Related Prisys capabilities
- ▪NHP heart failure model
- ▪Cynomolgus monkey heart failure samples
- ▪Translational tissue and biomarker studies
- ▪Cardiovascular pharmacology support
- ▪Collaborative research material provision
An optimal animal model of ischemic stroke established by digital subtraction angiography-guided autologous thrombi in cynomolgus monkeys
Frontiers in Neurology·2022·Peer-reviewed research article·CNS and cerebrovascular research
Study overview
This study described the development and evaluation of a cynomolgus monkey model of focal ischemic stroke. Autologous thrombi were introduced under digital subtraction angiography (DSA) guidance to produce middle cerebral artery occlusion.
The study combined DSA, CT angiography, CT perfusion, MRI, MR angiography, neurological assessment, thrombolytic intervention and post-mortem infarct evaluation. This design allowed the investigators to assess vascular occlusion, cerebral perfusion, neurological changes, treatment response and infarct formation within the same experimental framework.
Prisys involvement
Prisys Biotechnologies was listed among the author affiliations, with Prisys-affiliated researchers contributing to the study. The publication also identified a Prisys-related animal research ethics framework in the study information.
Related Prisys capabilities
- ▪NHP cerebrovascular disease models
- ▪DSA-guided procedures
- ▪clinical imaging
- ▪CNS pharmacology and treatment-response assessment
- ▪Neurological and imaging-based endpoints
Development of a unilateral ureteral obstruction model in cynomolgus monkeys
Animal Models and Experimental Medicine·2021·Peer-reviewed research article·Renal disease and fibrosis
Study overview
This collaborative study translated the unilateral ureteral obstruction model from rodents to cynomolgus monkeys to support the evaluation of therapeutic approaches for chronic kidney disease and renal fibrosis.
The study focused on the slower development of disease in cynomolgus monkeys compared with rodents and characterized the progression of tubulointerstitial fibrosis over time. The reported findings included advanced fibrosis at six weeks, a pattern of tubular basement membrane expansion and fibroblast infiltration that was considered relevant to human obstructive kidney disease, and an association between fibrosis and increased transglutaminase activity.
Prisys involvement
The publication included Prisys-affiliated researchers from the Prisys research and development team. It is therefore presented as a collaborative NHP model-development publication rather than as a publication authored solely by Prisys.
Related Prisys capabilities
- ▪Cynomolgus monkey renal disease models
- ▪Chronic kidney disease and renal fibrosis research
- ▪Histopathology and tissue-based endpoints
- ▪Translational evaluation of human-specific therapeutics
- ▪Collaborative model development for biopharmaceutical programs
BJTJ-1837, a novel FXI activation-blocking antibody
Research and Practice in Thrombosis and Haemostasis·2023·Peer-reviewed research article·Hematology, thrombosis and anticoagulant drug development
Study overview
This publication reported the preclinical evaluation of BJTJ-1837, an antibody designed to block the activation of coagulation factor XI. The study examined the antibody's effects on coagulation-related measures and antithrombotic activity, including experiments in cynomolgus monkeys.
The NHP work included an arteriovenous shunt model for assessment of thrombus formation and bleeding-time measurements for evaluation of bleeding-related safety. These endpoints are commonly considered together in the development of anticoagulant therapies because antithrombotic activity needs to be interpreted alongside potential effects on hemostasis.
Prisys involvement
The study was led by external research and biopharmaceutical teams. Prisys Biotechnologies supported the NHP research program through cynomolgus monkey thrombosis and bleeding-related experimental services. The publication is therefore categorized as a partner publication supported by Prisys, not as a Prisys-authored article.
Related Prisys capabilities
- ▪Cynomolgus monkey AV-shunt thrombosis model
- ▪Bleeding-time assessment
- ▪Coagulation and hematology testing
- ▪Antithrombotic pharmacology
- ▪NHP safety and tolerability assessment
- ▪Comparative evaluation of anticoagulant candidates
Modeling warfarin-associated intracerebral hemorrhage in cynomolgus monkeys
Blood·2014·Conference abstract·Hematology, cerebrovascular disease and anticoagulant safety
Study overview
This conference abstract described a cynomolgus monkey model of intracerebral hemorrhage and examined the effect of warfarin treatment on hematoma volume and related outcomes.
The model used collagenase injection to induce intracerebral hemorrhage. MRI was used to measure hematoma changes over time, while coagulation testing and treatment with fresh frozen plasma and vitamin K were used to examine clinically relevant interventions.
Prisys involvement
Multiple authors were affiliated with Prisys Biotechnologies. Because the record is a conference abstract rather than a full-length research article, it is listed separately on this page.
Related Prisys capabilities
- ▪CNS and stroke models
- ▪MRI-based hematoma assessment
- ▪Anticoagulant and hemostasis research
- ▪Coagulation testing
- ▪Evaluation of plasma and vitamin K interventions
Sustained antidepressant-like effects of psychedelics through 5-HT2AR–β-arrestin signaling
Nature Neuroscience·2026·Peer-reviewed research article·CNS pharmacology, psychedelic compounds and NHP behavioral research
Study overview
This study investigated the role of 5-HT2A receptor (5-HT2AR) signaling, particularly the β-arrestin pathway, in the sustained antidepressant-like effects of psychedelic compounds. Combining receptor signaling studies, compound design and in vivo experiments, the research identified β-arrestin signaling as a contributor to sustained antidepressant-like effects in mouse models.
The study also incorporated cynomolgus monkey experiments to characterize behavioral and functional responses to psychedelic compounds. Assessments included spontaneous behavioral analysis, motor function testing and cognitive task performance, providing complementary information on compound-related effects in a non-human primate model.
Prisys involvement
Prisys Biotechnologies conducted the cynomolgus monkey experimental work reported in this publication, and a Prisys-affiliated researcher is among the co-authors. Prisys performed 3D behavioral analysis using synchronized multi-view video acquisition and computer vision-based posture reconstruction, alongside motor function assessment through beam-walking tests and cognitive evaluation using delayed matching-to-sample (DMTS) tasks. Related pharmacokinetic sampling was also conducted as part of the NHP study. The original article remains the source of record for authorship, methods and results.
Related Prisys capabilities
- ▪Cynomolgus monkey models and NHP pharmacology studies
- ▪3D NHP behavioral analysis and quantitative behavioral phenotyping
- ▪NHP motor function assessment and beam-walking tests
- ▪NHP cognitive function assessment and DMTS tasks
- ▪Pharmacokinetic sampling and integrated PK/PD research
- ▪CNS drug research and functional endpoint evaluation
Research themes represented in these publications
The publications listed above cover several areas in which NHP models can support translational research:
CNS and cerebrovascular research
Cynomolgus monkey stroke and intracerebral hemorrhage models can incorporate clinically relevant vascular procedures, MRI-based assessment, neurological endpoints and treatment interventions.
Hematology, hemophilia and thrombosis
NHP models can be used to evaluate biologic therapies for hemophilia, antithrombotic activity, coagulation, hemostasis and safety-related endpoints.
Renal disease, fibrosis and target engagement
Cynomolgus monkey renal models can help researchers evaluate disease progression, target engagement and human-specific therapeutic approaches when rodent cross-reactivity is limited.
Cardiovascular disease and gene therapy
NHP heart failure samples and cardiovascular models can support translational analysis of disease-associated tissue changes, biomarkers and therapeutic mechanisms.
Integrated study design
These studies also illustrate the value of combining model induction with imaging, pharmacology, clinical pathology, histopathology and longitudinal assessment. The appropriate combination depends on the therapeutic modality, disease question and development stage.
How Prisys is represented in the publication record
Prisys may be associated with a publication in more than one way. The publication record on this page uses the following distinctions:
The original publication remains the authoritative source for the study's authorship, methods, results and disclosures. Prisys does not reproduce full articles on this page. Instead, each record provides a concise description and links to the publisher's version of record or the relevant conference record.
Frequently asked questions
Q: What types of publications are included on this page?
A: The page includes selected peer-reviewed articles, collaborative NHP model-development studies, partner publications supported by Prisys, and conference abstracts involving Prisys-affiliated research or documented Prisys research support.
Q: Does every listed publication represent a Prisys-authored study?
A: No. Some records include Prisys-affiliated authors, while others are partner publications supported through Prisys NHP models or experimental services. The role of Prisys is identified in each record.
Q: Which NHP species and models are represented?
A: The selected records include NHP research related to hemophilia, ischemic stroke, intracerebral hemorrhage, renal fibrosis, target engagement, cardiovascular disease and arteriovenous shunt thrombosis. The animal and tissue models include cynomolgus monkey studies, cynomolgus monkey heart failure samples, mouse disease models and human cell-based models. Additional disease areas and models will be added as publications are verified and approved for inclusion.
Q: Can Prisys support a publication-oriented NHP study?
A: Prisys can discuss NHP model selection, pharmacology, safety evaluation, imaging, biomarkers, sample collection and other study components as part of a preclinical research program. The appropriate study design depends on the therapeutic modality, disease area, endpoints and development stage.
Q: How can I discuss a research program with Prisys?
A: To discuss a potential NHP study or collaborative research program, contact the Prisys Biotechnologies team at bd@prisysbiotech.com.
Contact Prisys Biotechnologies
If you are evaluating an NHP model for pharmacology, safety assessment, translational research or mechanism-of-action studies, the Prisys team can discuss the model, endpoints and supporting capabilities relevant to your program.
This page is reviewed and updated as publications are verified and approved for inclusion. Last reviewed: September 2026.
